Servicio de Hematología, Hospital Universitario de Salamanca, Paseo de San Vicente, 58-182, Salamanca, 37007, Spain.
Ann Hematol. 2013 Jan;92(1):97-100. doi: 10.1007/s00277-012-1566-3. Epub 2012 Sep 7.
We have evaluated the use of CD138+ positively selected bone marrow samples to identify a molecular target for minimal residual disease assessment by polymerase chain reaction (PCR) in 25 untreated patients with multiple myeloma. A fraction of each sample was used for CD138+ selection, and the rest served as a reference control. VDJH, DJH, and Kde gene rearrangements were tested for amplification according to the BIOMED-2 Concerted Action. PCR products were directly sequenced in an automated ABI 3130 DNA sequencer using Big-Dye terminators. Within the CD138+ selected group, VDJH rearrangements were detected in all cases (100 %), DJH in 16 (64 %), and Kde in 18 (72 %) cases; whereas in the control samples, VDJH, DJH, and Kde rearrangements were detected in 19 (76 %), 11 (44 %), and 12 (48 %) cases, respectively. After sequencing, 24 (96 %) cases within the CD138+ group had a PCR target for MRD detection compared with 15 (60 %) cases in the control group. We conclude that the use of CD138+ positively selected bone marrow samples increases the applicability of minimal residual disease studies by PCR in patients with multiple myeloma.
我们评估了使用 CD138+阳性选择的骨髓样本，通过聚合酶链反应 (PCR) 来鉴定多发性骨髓瘤 25 例未经治疗患者微小残留病评估的分子靶标。每个样本的一部分用于 CD138+选择，其余部分作为参考对照。根据 BIOMED-2 协同行动，测试了 VDJH、DJH 和 Kde 基因重排的扩增。PCR 产物在自动 ABI 3130 DNA 测序仪上使用 Big-Dye 终止子直接测序。在 CD138+选择组中，所有病例（100%）均检测到 VDJH 重排，16 例（64%）检测到 DJH，18 例（72%）检测到 Kde；而在对照样本中，19 例（76%）、11 例（44%）和 12 例（48%）分别检测到 VDJH、DJH 和 Kde 重排。测序后，CD138+组 24 例（96%）与对照组 15 例（60%）相比，有 PCR 检测微小残留病的靶标。我们得出结论，使用 CD138+阳性选择的骨髓样本增加了多发性骨髓瘤患者通过 PCR 进行微小残留病研究的适用性。
